Читать книгу Intracranial Gliomas Part III - Innovative Treatment Modalities - Группа авторов - Страница 58

1Kinoshita M, Yamada K, Hashimoto N, Kato A, Izumoto S, Baba T, Maruno M, Nishimura T, Yoshimine T: Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition: initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. Neuroimage 2005;25:424–429.

2Muragaki Y, Iseki H, Maruyama T, Kawamata T, Yamane F, Nakamura R, Kubo O, Takakura K, Hori T: Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl 2006;98:67–75.

3Berman JI, Berger MS, Chung SW, Nagarajan SS, Henry RG: Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging. J Neurosurg 2007;107:488–494.

4Russell SM, Kelly PJ: Incidence and clinical evolution of postoperative deficits after volumetric stereotactic resection of glial neoplasms involving the supplementary motor area. Neurosurgery 2007;61(1 suppl Clinical Neurosurgery):358–368.

5Stadlbauer A, Nimsky C, Buslei R, Salomonowitz E, Hammen T, Buchfelder M, Moser E, Ernst-Stecken A, Ganslandt O: Diffusion tensor imaging and optimized fiber tracking in glioma patients: histopathologic evaluation of tumor-invaded white matter structures. Neuroimage 2007;34:949–956.

6Yamada S, Muragaki Y, Maruyama T, Komori T, Okada Y: Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas. Clin Neurol Neurosurg 2015;130:134–139.

7Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, Weinstein AS, Nelson DF: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239–244.

8Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95:735–745.

9Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392–401.

10Tsitlakidis A, Foroglou N, Venetis CA, Patsalas I, Hatzisotiriou A, Selviaridis P: Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. J Neurosurg 2010;112:1020–1032.

11Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338–1345.

12McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156–162.

13Duffau H: A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. Neurochirurgie 2013;59:2–8.

14Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME: Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522–3528.

15Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288–2294.

16Duffau H, Capelle L: Preferential brain locations of low-grade gliomas. Cancer 2004;100:2622–2626.

17Mandonnet E, Capelle L, Duffau H: Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol 2006;78:179–185.

18Claes A, Idema AJ, Wesseling P: Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007;114:443–458.

19Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 1982;12:231–237.

20van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–2722.

21Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 2008;44:1210–1216.

22Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O’Neill BP, Giannini C, Brown PD: Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 2009;11:437–445.

23Kreth FW, Warnke PC, Scheremet R, Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762–766.

24Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C: Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003;14:305–312.

25Maroon JC, Onik G, Quigley MR, Bailes JE, Wilberger JE, Kennerdell JS: Cryosurgery re-visited for the removal and destruction of brain, spinal and orbital tumours. Neurol Res 1992;14:294–302.

26Gage AA, Baust JG: Cryosurgery for tumors. J Am Coll Surg 2007;205:342–356.

27Li M, Liu J, Zhang SZ, Zhou Y, Guo YW, Chen Q, Ke YQ, Jiang XD, Cai YQ: Cellular immunologic response to primary cryoablation of C6 gliomas in rats. Technol Cancer Res Treat 2011;10:95–100.

28Kandel EI, Biezin OA: [Cryosurgery of brain tumors]. Vopr Neirokhir 1971;35(1):3–9 (in Russian).

29Hoshino T: Cell kinetics of glial tumors. Rev Neurol (Paris) 1992;148:396–401.

30Decan VS, Parfenov VE, Trufanov GE, Martynov BV, Svistov DV, Romanov GG: [Improvement of estimation of the glial tumor malignancy with radionuclide study]. Vestnik Russian Military Med Acad 2010;N2(30):12–18 (in Russian).

31Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–820.

32Nizkovolos VB: [A device for stereotactic cryoneurosurgery using solid carbon dioxide]. Med Tekh 2012;N6:37–41 (in Russian).

33Gage AА, Baust J: Mechanisms of tissue injury in cryosurgery. Cryobiology 1998;37:171–186.

34Polonsky YZ, Kholyavin AI, Martynov BV, Parfenov VE, Trufanov GE: [Frameless calculated MRI with Oreol stereotactic manipulators]. Vestnik Russian Military Med Acad 2009;N4(28):71–78 (in Russian).

35Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ: Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 2008;150:23–29.

36Carrabba G, Fava E, Giussani C, Acerbi F, Portaluri F, Songa V, Stocchetti N, Branca V, Gaini SM, Bello L: Cortical and subcortical motor mapping in rolandic and perirolandic glioma surgery: impact on postoperative morbidity and extent of resection. J Neurosurg Sci 2007;51:45–51.

37Kumabe T, Higano S, Takahashi S, Tominaga T: Ischemic complications associated with resection of opercular glioma. J Neurosurg 2007;106:263–269.

38Duffau H: A personal consecutive series of surgically treated 51 cases of insular WHO Grade II glioma: advances and limitations. J Neurosurg 2009;110:696–708.

39Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R: GNOSIS: Guidelines for Neuro-Oncology: standards for investigational studies – reporting of surgically based therapeutic clinical trials. J Neurooncol 2007;82:211–220.

40Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK: Response and progression in recurrent malignant glioma. Neuro Oncol 1999;1:282–288.

41Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004;6:227–235.

42Kelly PJ: Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery 1989;25:185–195.

43Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–710.

44Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y: Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 1994;21:177–185.

45Gaudin PB, Sherman ME, Brat DJ, Zahurak M, Erozan YS: Accuracy of grading gliomas on CT-guided stereotactic biopsies: a survival analysis. Diagn Cytopathol 1997;17:461–466.

46Malham G, Moonesinghe S, Synek B, Anderson N, Bok A: Low-grade supratentorial astrocytomas in adults: management, immunohistochemical analysis and long-term follow-up. J Clin Neurosci 1998;5:304–309.

47van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C: Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998;64:581–587.

48Iwabuchi S, Bishara S, Herbison P, Erasmus A, Samejima H: Prognostic factors for supratentorial low grade astrocytomas in adults. Neurol Med Chir (Tokyo) 1999;39:273–281.

49Keles GE, Anderson B, Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999;52:371–379.

50Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, Volk B, Ostertag CB: The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999;86:2117–2123.

51Johannesen TB, Langmark F, Lote K: Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg 2003;99:854–862.

52Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467–473.

53Ushio Y, Kochi M, Hamada J, Kai Y, Nakamura H: Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo) 2005;45:454–461.

Dmitry V. Svistov, MD

Department of Neurosurgery, Military Medical Academy

Pirogovskaya Emb., 3

Saint Petersburg 194044 (Russia)

E-Mail dvsvistov@mail.ru